Background: Extended interval dosing of natalizumab is associated with significantly lower progressive multifocal leukoencephalopathy risk compared with every-4-week (Q4W) dosing in patients with relapsing-remitting multiple sclerosis. Previous studies have suggested that natalizumab effectiveness is maintained in patients who switch from Q4W to extended interval dosing but have been limited by a lack of well-matched patient cohorts. Methods: Tysabri Observational Program (TOP) data as of November 2019 were used to identify patients with relapsing-remitting multiple sclerosis treated with natalizumab Q4W and those with a single physician-indicated dosing change from Q4W to every-6-week (Q6W) dosing after ⩾1 year of Q4W treatment. Patients w...
Introduction Natalizumab (NTZ) is one of the most effective treatment options for multiple sclerosis...
BACKGROUND: Natalizumab is efficacious in the treatment of relapsing-remitting multiple sclerosis. A...
BACKGROUND: Accumulating evidence supports the efficacy of administering natalizumab (NZ) with exten...
Background Treatment with natalizumab once every 4 weeks is approved for patients with relapsing-rem...
Background: The enthusiasm for natalizumab, a highly efficacious agent in the treatment of multiple ...
OBJECTIVE: To determine whether natalizumab efficacy is maintained when switching to personalized ex...
Extending the natalizumab interval after the 24th administration could reduce the risk of progressiv...
BACKGROUND: Natalizumab is an effective treatment in relapsing-remitting multiple sclerosis (MS). Ma...
Objective: To compare treatment efficacy and persistence in patients who switched to natalizumab ver...
IMPORTANCE The evaluation of therapeutic choices is needed after 24 doses of natalizumab in patients...
BACKGROUND: Clinical trials established the efficacy and safety of natalizumab. Data are needed over...
Introduction Natalizumab (NTZ) is one of the most effective treatment options for multiple sclerosis...
BACKGROUND: Natalizumab is efficacious in the treatment of relapsing-remitting multiple sclerosis. A...
BACKGROUND: Accumulating evidence supports the efficacy of administering natalizumab (NZ) with exten...
Background Treatment with natalizumab once every 4 weeks is approved for patients with relapsing-rem...
Background: The enthusiasm for natalizumab, a highly efficacious agent in the treatment of multiple ...
OBJECTIVE: To determine whether natalizumab efficacy is maintained when switching to personalized ex...
Extending the natalizumab interval after the 24th administration could reduce the risk of progressiv...
BACKGROUND: Natalizumab is an effective treatment in relapsing-remitting multiple sclerosis (MS). Ma...
Objective: To compare treatment efficacy and persistence in patients who switched to natalizumab ver...
IMPORTANCE The evaluation of therapeutic choices is needed after 24 doses of natalizumab in patients...
BACKGROUND: Clinical trials established the efficacy and safety of natalizumab. Data are needed over...
Introduction Natalizumab (NTZ) is one of the most effective treatment options for multiple sclerosis...
BACKGROUND: Natalizumab is efficacious in the treatment of relapsing-remitting multiple sclerosis. A...
BACKGROUND: Accumulating evidence supports the efficacy of administering natalizumab (NZ) with exten...